Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Phase 3
Active, not recruiting
NCT03375320
| Condition | Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1 |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | National Cancer Institute (NCI) |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 298 participants |
|---|
| Interventions | Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration |
|---|
| Start date | Oct 26, 2018 |
|---|
| Completion date | Aug 23, 2023 |
|---|
| Results posted | Oct 16, 2024 |
|---|
Summary
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
Progression-free Survival (PFS)
36 months · months
| Arm Ia (Cabozantinib S-malate, Extra-pancreatic NET Cohort [epNET]) | 8.4 months |
|---|
| Arm IIa (Placebo, Extra-pancreatic NET Cohort [epNET]) | 3.9 months |
|---|
| Arm Ib (Cabozantinib S-malate, Pancreatic NET Cohort [pNET]) | 13.8 months |
|---|
| Arm IIb (Placebo, Pancreatic NET Cohort [pNET]) | 4.4 months |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.